Metagenomi, Inc. (MGX) AI Stock Analysis

• Market Cap: $51.92M
• Dividend Yield: N/A
• Average Volume (3M): 883.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: -43.88%
• EPS Growth: 4.73%
• Country: US
• Employees: 202
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 37,620,530
• 10 Day Avg. Volume: 1,405,864
• 30 Day Avg. Volume: 883,524
• PEG Ratio: -0.05
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 2.39
• P/FCF Ratio: -0.67
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 2.09
• Enterprise Value/Gross Profit: 667.50
• Enterprise Value/Ebitda: -0.60
• 1Y Price Target: $9.50
• Price Target Upside: 578.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -2.09
• Revenue Forecast (FY): $26.23M

• Rating: 47 Neutral
• Price Target: $1.50 ▲(7.14% Upside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

Score is held back primarily by persistent large losses and significant cash burn with declining equity, indicating elevated funding and execution risk. Technicals are neutral-to-mixed (short-term improvement but long-term downtrend), while valuation is difficult to support given negative earnings and no dividend. Corporate updates are constructive, especially the extended runway and pipeline milestones, but do not offset weak financial performance.

Positive Factors

Extended Cash Runway & Strategic Focus

Extending projected cash runway through Q4 2027 and completing a pre-IND meeting materially reduces near-term financing pressure and regulatory uncertainty. This gives management time to advance preclinical assets, achieve de-risking milestones, and pursue non-dilutive partnerships, improving execution odds over the next 2–6 months.

Negative Factors

Large Persistent Cash Burn

Sustained free cash flow deficits (~-$89M) mean the company must continually access external capital or cut investment. Persistent cash burn elevates dilution and execution risk, constrains long-term program funding choices, and increases dependence on milestone/licensing deals that may be uncertain within a 2–6 month horizon.

Metagenomi, Inc. Business Overview & Revenue Model

Company Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, ...

Read more

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, ...

How the Company Makes Money

Metagenomi’s revenue model is primarily based on research collaborations and licensing/technology access arrangements rather than product sales, as the company is in a development stage and does not have marketed therapeutics. Under these arrangem...

Read more

Metagenomi’s revenue model is primarily based on research collaborations and licensing/technology access arrangements rather than product sales, as the company is in a development stage and does not have marketed therapeutics. Under these arrangem...

Metagenomi, Inc. Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	25.21M	52.30M	44.76M	17.20M	243.00K
Gross Profit	19.89M	52.30M	-49.65M	15.47M	-144.00K
EBITDA	-90.70M	-83.49M	-74.28M	-39.19M	-20.75M
Net Income	-87.87M	-78.06M	-68.25M	-43.59M	-21.44M
Balance Sheet
Total Assets	221.10M	324.60M	364.84M	414.49M	141.99M
Cash, Cash Equivalents and Short-Term Investments	160.80M	248.31M	271.18M	362.13M	108.15M
Total Debt	40.66M	45.78M	48.23M	18.57M	48.93M
Total Liabilities	62.51M	89.74M	149.67M	488.91M	174.54M
Stockholders Equity	158.60M	234.86M	215.17M	-74.43M	-32.54M
Cash Flow
Free Cash Flow	-89.47M	-112.19M	-101.22M	15.75M	21.35M
Operating Cash Flow	-88.89M	-109.07M	-91.41M	29.72M	24.26M
Investing Cash Flow	103.53M	-88.16M	45.73M	-122.20M	-74.32M
Financing Cash Flow	-356.00K	84.01M	1.01M	239.59M	39.92M

Metagenomi, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Neutral. The current price of 1.4 is above the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.47, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 47.74 is Neutral, neither overbought nor oversold. The STOCH value of 72.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MGX.

Metagenomi, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	61 Neutral	$142.78M	1.57	43.14%	―	―	814.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNTX	50 Neutral	$228.78M	-3.87	-47.04%	―	―	69.30%
MGX	47 Neutral	$51.92M	-0.69	-40.87%	―	-43.88%	4.73%
IMUX	47 Neutral	$152.64M	-8.55	-1197.81%	―	―	30.16%
HOWL	44 Neutral	$41.26M	-0.48	-122.43%	―	-100.00%	-8.30%
ATRA	42 Neutral	$38.03M	-16.66	-79.12%	―	51.27%	―